[Improvement of growth-hormone stimulation with l-dopa/l-carbidopa by simultaneous administration of propranolol...

Area of Science:

• Pediatric Endocrinology
• Pharmacology

Background:

• Growth hormone (GH) deficiency is a significant cause of growth retardation in children.
• L-dopa and L-carbidopa are used to stimulate GH secretion, but some children remain unresponsive.
• Propranolol's effect on GH secretion in conjunction with L-dopa/L-carbidopa requires further investigation.

Purpose of the Study:

• To evaluate the effect of combined L-dopa/L-carbidopa and propranolol administration on growth hormone secretion in children with growth retardation.
• To compare the efficacy of combined therapy versus L-dopa/L-carbidopa alone in improving GH response.
• To assess the safety and practicality of the combined treatment regimen.

Main Methods:

• Ninety-six children with growth retardation were studied.
• One group received L-dopa (250 mg) + L-carbidopa (25 mg) plus propranolol (1 mg/kg, max 40 mg).
• A control group received only L-dopa and L-carbidopa. Growth hormone levels were measured at 0, 45, and 90 minutes.

Main Results:

• The addition of propranolol reduced the non-response rate to GH stimulation from 16% to 9.5%.
• No significant difference in peak GH levels was observed, but propranolol prolonged the GH rise.
• Some previously unresponsive children showed satisfactory GH stimulation with the combined therapy.

Conclusions:

• Combined administration of L-dopa/L-carbidopa and propranolol enhances growth hormone secretion in a subset of children with growth retardation.
• The combined treatment leads to a more sustained increase in serum growth hormone levels.
• The regimen is well-tolerated, requires minimal blood sampling, and is suitable for outpatient use.